State University of New York

KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

Retrieved on: 
星期三, 十一月 8, 2023
Pharmaceutical, Health, Medical Supplies, Medical Devices, Linda, KRMD, Worldwide, Security (finance), NYSE, International, Compensated emancipation, Life, Master of Business Administration, University of Chicago, Laboratory, EBITDA, Roche, Novo Nordisk, Cyprus Securities and Exchange Commission, Organization, Reckitt, NASCO, University of Chicago Booth School of Business, Quality of life, Growth, BDX, Business administration, Marketing, Employment, Business, State university system, University, BD (company), Chief commercial officer, Patient, State University of New York, Pharmaceutical industry, Management

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023.

Key Points: 
  • KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023.
  • As Chief Commercial Officer, Ken will have oversight of the global commercial function including U.S. and International sales and marketing organizations.
  • He joins KORU Medical with impressive medical device and pharmaceutical industry experience, most recently from NASCO Healthcare where he spent five years as President & CEO.
  • Ken also held leadership roles in marketing, sales, and business development with Novo Nordisk, Adams Respiratory Therapeutics, and Roche Laboratories.

MTV Entertainment Studios and Active Minds announce national campaign "A.S.K." to address critical youth mental health challenge

Retrieved on: 
星期二, 十月 10, 2023
Courage, MTV Video Music Awards, MTV, Florida State University, Roll, Organization, State University of New York, University, Mental health, Environment, Active Minds, PSAS, Friends, Cupertino Union School District, Paramount Media Networks, Fort Collins, Colorado, MTV Entertainment Studios, SHOWTIME, City, Mississippi State University, College of Southern Nevada, Research, Nursing, Toy, Canal, Casino, Private investigator, Harbor, Citrus

NEW YORK, Oct. 10, 2023 /PRNewswire/ -- MTV Entertainment Studios (MTVE) has partnered with leading young adult mental health non-profit Active Minds to spearhead an innovative mental health campaign this fall that empowers youth and young adults to simply and effectively help people in their lives through emotional challenges. Called A.S.K. - an acronym for Acknowledge, Support, and Keep-In-Touch - the new highly memorable, multi-media campaign will roll out via digital-first marketing and at key cultural events and on campuses nationwide this fall, combining Active Minds' two decades of expertise championing peer-to-peer mental health programs for youth and young adults with the global platform of MTVE's Mental Health is Health initiative.

Key Points: 
  • MTV research finds that young people want to support their friends, but nearly 70% do not feel prepared to do so.
  • "MTV Entertainment is committed to driving meaningful change in youth mental health through powerful storytelling, insights, and tools that move people from awareness toward action," said Chris McCarthy, President and CEO, SHOWTIME/MTV Entertainment Studios and Paramount Media Networks.
  • "We are excited to partner with Active Minds to recruit an army of peer health allies to empower young people to support their friends, families and communities."
  • "I am thrilled to continue working with MTVE and Active Minds, two organizations that value the mental health and well being of marginalized youth and young adults," said Morgann Noble, youth advisor.

Boyden Asia Pacific Welcomes Technology Trailblazer, Melody Chang

Retrieved on: 
星期三, 九月 6, 2023
State University of New York, Melody, Big data, Marketing, Stanford University, National Taiwan University, State university system, Income tax, Statistics, MBA, Engineering, Artificial intelligence, National Chengchi University, Mathematics, Ali Baba, Economics, Sales, Management, Internet of things, Tencent, Chinese, AI

Shanghai, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Boyden, a premier global leadership and talent advisory firm, welcomes Melody Chang, who joins as Principal, based in Shanghai and member of Boyden’s global technology practice.

Key Points: 
  • Shanghai, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Boyden, a premier global leadership and talent advisory firm, welcomes Melody Chang, who joins as Principal, based in Shanghai and member of Boyden’s global technology practice.
  • “I love technology and when I saw how rapidly the China market was changing and stimulating the development of innovative technologies, I had to become part of that change,” commented Melody Chang, Principal, Boyden Shanghai.
  • The Boyden team in Asia Pacific are sincere, visionary leaders who share my commitment to the Chinese market, and show me a grand possibility for what can be achieved in Boyden with dynamic and well-connected international collaboration.
  • Melody holds a Certificate in Chinese-English simultaneous interpreter training from the China Productivity Centre, and a government-funded Certificate in technology management from National Chengchi University.

Vencanna Announces Amended Definitive Agreement with Cannavative Group and Provides Operational Update

Retrieved on: 
星期三, 八月 16, 2023
Treasury Wine Estates, AB, MBA, Balance sheet, Cosmetic, New Jersey Cannabis Regulatory Commission, Acquisition, Investment, Patient, State University of New York, Transaction, University, Chase Bank, LEED AP, Friends, TGC, DeGroote School of Business, Plastic, Cannabis, Growth, ATC, NFP, CSE, Canadian Securities Exchange, Multichannel multipoint distribution service, Health, Beer, Business, MillerCoors, SOP, Gold, Control, Physics, CFO, Research, Hand, Family, Rotman School of Management, CGT, CRC, Theoretical physics, College of Medicine, Debenture, CSA, Sadness, University of Texas at Austin, CPA, SVKM's NMIMS, Warrant (finance), Wine, Security (finance), Sales, Crown

"Vencanna Ventures" (the "Company" or "Vencanna") (CSE: VENI) (OTCQB: TPPRF) provides the following corporate and operational updates:

Key Points: 
  • "Vencanna Ventures" (the "Company" or "Vencanna") (CSE: VENI) (OTCQB: TPPRF) provides the following corporate and operational updates:
    Effective today, the Company and The Cannavative Group LLC ("Cannavative") have amended and restated the definitive unit exchange agreement originally entered into on April 25, 2022 (as amended, the "A&R Definitive Agreement").
  • The Transaction value is US$12.5 million based on a deemed issue price of US$0.075 per Share (excluding the Earn-out Units).
  • Vencanna intends to seek shareholder approval of the Transaction by way of written resolution from shareholders holding not less than 50% plus one Share.
  • However, it is with great sadness to announce the recent passing of Mr. Ross Kline, founder, chairman, and CEO of the Cannavative Group.

The Standard Promotes Dickson Kasamale to Second Vice President of IT Finance and Analytics

Retrieved on: 
星期一, 八月 7, 2023
Professional Services, Insurance, Human Resources, Finance, Technology Business Management Council, IBM, State University of New York, Education, Standard Insurance Company, Culture, State university system, TBM, Multimedia, Economics, Standard, The Standard, Health Care Service Corporation, Corporate finance, Accounting, Management, Apptio

Standard Insurance Company (The Standard) announced today that Dickson Kasamale has been promoted to second vice president of IT Finance and Analytics in Corporate Finance and Accounting.

Key Points: 
  • Standard Insurance Company (The Standard) announced today that Dickson Kasamale has been promoted to second vice president of IT Finance and Analytics in Corporate Finance and Accounting.
  • View the full release here: https://www.businesswire.com/news/home/20230807104039/en/
    Dickson Kasamale, second vice president of IT Finance and Analytics at The Standard.
  • (Photo: Business Wire)
    Kasamale joined The Standard in 2019 as senior director of IT Finance.
  • “Dickson is a proven leader and trusted partner in our IT organization,” said Rob Erickson, vice president, chief accounting officer and treasurer at The Standard.

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Retrieved on: 
星期一, 七月 24, 2023
Inflammation, PDMA, Amgen, BS, Sabine Lisicki, Therapy, State University of New York, Arena Pharmaceuticals, Compensation, State university system, EMA, Economics, Acquisition, Immunology, Regeneron Pharmaceuticals, FDA, Pfizer, Pharmaceutical industry, Pain, Circulatory system

PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees.

Key Points: 
  • PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees.
  • "I look forward to leaning on his executive experience and commercial vision as a member of the Cadrenal board."
  • "I believe Cadrenal Therapeutics is developing a novel and potentially paradigm-changing therapeutic," said Robert Lisicki.
  • Lisicki will occupy a newly created seat on the Cadrenal Board of Directors.

How does the new over-the-counter birth control pill, Opill, work to prevent pregnancy? 5 questions answered

Retrieved on: 
星期三, 七月 19, 2023
People, Blood pressure, Vaginal bleeding, Review, Seizure, Insurance, State University of New York, Pregnancy, Headache, Conversation, Thrombus, Bleeding, Thornburgh v. American College of Obstetricians & Gynecologists, Diarrhea, Breast, Pharmacy, Pulmonary embolism, Neoplasm, HIV/AIDS, Progesterone, Binghamton University, Ovulation, Infection, State university system, Woman, Acne, Appetite, Uterus, Hormone, Provisions of the Affordable Care Act, Fatigue, Vomiting, Pharmacist, Food and Drug Administration, Norgestrel, Affordable Care Act, Tuberculosis, Time, Risk, OTC, Vertically transmitted infection, Deep vein thrombosis, Nausea, Growth, American College, FDA, Pulmonary hypertension, Mucus, Safety, Hormonal contraception, Food, Female, Breast cancer, Legislation, Birth control, Pharmaceutical industry

The Food and Drug Administration’s July 13, 2023, approval of the first over-the-counter birth control pill, called Opill, broadens the options for people seeking to prevent pregnancy.

Key Points: 
  • The Food and Drug Administration’s July 13, 2023, approval of the first over-the-counter birth control pill, called Opill, broadens the options for people seeking to prevent pregnancy.
  • When Opill becomes available, presumably in the first quarter of 2024, it will be sold in grocery and convenience stores, in pharmacies and through online retailers.

1. How does Opill work to prevent pregnancy?

    • Opill, like many other progestin-only birth control pills, must be taken at the same time each day to prevent pregnancy.
    • This is because progestin has to stay at a certain level in the body in order to effectively prevent pregnancy.
    • Opill does not prevent sexually transmitted infections, so people looking to further protect themselves should still use some sort of barrier method during intercourse.

2. Is Opill safe to be sold over the counter?

    • The same drug in Opill, norgestrel, has been used safely and effectively for birth control since 1973.
    • In order for a drug to be sold without a prescription in the U.S., it must first be reviewed and approved by the Food and Drug Administration.
    • Several studies have looked at whether women can accurately evaluate their own ability to safely use birth control.

3. Shouldn’t a doctor be involved in choosing birth control?

    • Screenings may include pap test, pelvic examination, clinical breast examination and testing for sexually transmitted diseases.
    • Even before the approval of Opill, people had the option to uncouple their screening examinations from prescription access.
    • In addition, more than 20 states currently allow pharmacists to provide prescription contraceptive based on a self-assessment questionnaire and blood pressure screening.

4.Does Opill have any side effects?

    • Opill does not contain estrogen, as some other hormonal birth control pills do.
    • Estrogen plays a role in menstrual regularity, so people who use Opill may experience more irregular vaginal bleeding.
    • But some individuals who use Opill may have less bleeding or stop bleeding altogether while taking the pills.

5. Will OTC status truly increase accessibility to birth control?

    • The Affordable Care Act currently mandates insurance coverage of certain FDA-approved prescription birth control products, but it does not require coverage of nonprescription options.
    • Lastly, Opill represents only one type of birth control.
    • If 100 women use a birth control that is 91% effective over one year, it is estimated that nine women using that method will become pregnant over that year.

Alignment Health Names Chief Legal and Administrative Officer

Retrieved on: 
星期一, 七月 17, 2023
Medicaid, University, State University of New York, State university system, Economics, Alignment, Medicare, Patient, Growth, Pharmaceutical industry, Management

ORANGE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Continuing its forward momentum in 2023, Alignment Health — a consumer brand name of Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company — today announced the appointment of Christopher J. Joyce as its new chief legal and administrative officer (CLAO).

Key Points: 
  • ORANGE, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Continuing its forward momentum in 2023, Alignment Health — a consumer brand name of Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company — today announced the appointment of Christopher J. Joyce as its new chief legal and administrative officer (CLAO).
  • Joyce steps into the CLAO role effective Aug. 1, reporting to Alignment Health Founder and CEO John Kao.
  • “Chris brings a wealth of legal expertise and a proven track record of success to our organization.
  • His expertise spans securities laws, corporate governance, legal affairs, private and government reimbursement, finance, mergers and acquisitions, business development, operations management and health care compliance.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
星期四, 七月 13, 2023
State University of New York, AACR, EAP, GCC, Half-life, HPHA, ATAC, SRC, Binghamton University, Multiple myeloma, Clinical trial, State university system, Bone marrow, Cancer, American Association for Cancer Research, FSE, Magenta, Research, ATACS, Sale, Spanish mythology, Amanitin, Data analysis, CAIX, Patient, Antibody-drug conjugate, Microsoft Access, Marketing, CFO, Management, Ethics, ADC, Eli Lilly and Company, Depreciation, Spacecraft, Phase, FDA, Therapy, Market Access Program, Safety, Disease, Pharmaceutical industry, Vaccine, Fine chemical, Generic drug, Cryptocurrency, Telix, Emergence

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

Crossroads Hires New Chief Medical Officer

Retrieved on: 
星期二, 七月 11, 2023
Renaissance School of Medicine at Stony Brook University, State University of New York, IV, Yale Physician Associate Program, State university system, Buffalo, Loyola University, CMO, Anderson Regional Medical Center, Medical director, Patient, SUNY, University at Buffalo, Nursing

GREENVILLE, S.C., July 11, 2023 /PRNewswire/ -- Crossroads Treatment Centers (Crossroads) has announced the addition of Dr. James P. Stephen, M.D., as Chief Medical Officer (CMO).

Key Points: 
  • GREENVILLE, S.C., July 11, 2023 /PRNewswire/ -- Crossroads Treatment Centers (Crossroads) has announced the addition of Dr. James P. Stephen, M.D., as Chief Medical Officer (CMO).
  • In his role, Dr. Stephen will be responsible for providing strategic leadership for the medical operations of the organization.
  • He will also serve as a liaison with other medical professionals in the communities served by Crossroads.
  • Before joining Crossroads, Dr. Stephen was most recently Regional Medical Officer at leading home-health provider, Landmark Health, where he successfully established a home care delivery model and a national call coverage system, among other large company initiatives.